VHB937: VHB937 solution for infusion
Placebo: Solution for infusion
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).
| Facility | City | Region | Status |
|---|---|---|---|
| University of California San Diego | La Jolla | California | |
| Loma Linda University Health | Loma Linda | California | |
| Keck Medical Center USC | Los Angeles | California | |
| UC San Francisco Medical Center | San Francisco | California | |
| University of Miami | Miami | Florida | |
| Orlando Health Clinical Trials | Orlando | Florida | |
| Emory University School of Medicine | Atlanta | Georgia | |
| University Of Kansas Medical Center | Kansas City | Kansas | |
| Massachusetts General Hospital | Boston | Massachusetts | |
| University of Nebraska Medical Center | Omaha | Nebraska | |
| Lange Neurology PC | New York | New York | |
| University of Rochester Medical Center | Rochester | New York | |
| Atrium Health | Charlotte | North Carolina | |
| Duke University Health System | Durham | North Carolina | |
| Univ of Cincinnati Medical Center | Cincinnati | Ohio | |
| The Ohio State University | Columbus | Ohio | |
| Temple University | Philadelphia | Pennsylvania | |
| AMR Knoxville | Knoxville | Tennessee | |
| Austin Neuromuscular Center | Austin | Texas | |
| Nerve and Muscle Center of Texas | Houston | Texas | |
| University of Washington Medical Center | Seattle | Washington | |
| Novartis Investigative Site | North Ryde | New South Wales | |
| Novartis Investigative Site | Herston | Queensland | |
| Novartis Investigative Site | Caulfield South | Victoria | |
| Novartis Investigative Site | Southport | Australia | |
| Novartis Investigative Site | Leuven | Vlaams Brabant | |
| Novartis Investigative Site | Liège | Belgium | |
| Novartis Investigative Site | Calgary | Alberta | |
| Novartis Investigative Site | Montreal | Quebec | |
| Novartis Investigative Site | Beijing | China | |
| Novartis Investigative Site | Aalborg | Denmark | |
| Novartis Investigative Site | Kobenhavn N V | Denmark | |
| Novartis Investigative Site | Bron | France | |
| Novartis Investigative Site | Lille | France | |
| Novartis Investigative Site | Nice | France | |
| Novartis Investigative Site | Paris | France | |
| Novartis Investigative Site | Tours | France | |
| Novartis Investigative Site | Mannheim | Baden-Wurttemberg | |
| Novartis Investigative Site | Munich | Bavaria | |
| Novartis Investigative Site | Würzburg | Bavaria |
+ 34 more sites — see the full list on the official registry below.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06643481 on ClinicalTrials.gov ↗ ← All trials in Ireland